

TDMs No. 20310 - 02

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 912 Vehicle 9 mo M Include 913 AZT 40 9 mo M Include 914 AZT 80 9 mo M
Include 915 AZT 120 9 mo M

Study Gender: Male

TDMSE Version: 2.1.0

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle 9 mo M | AZT 40 9 mo M | AZT 80 9 mo M | AZT 120 9 mo M |
|---------------------------------------|----------------|---------------|---------------|----------------|
| Disposition Summary | | | | |
| Animals Initially in Study | 27 | 27 | 27 | 27 |
| Early Deaths | | | | |
| Moribund Sacrifice | 1 | 1 | | 1 |
| Natural Death | 1 | 2 | | 1 |
| Survivors | | | | |
| Moribund Sacrifice | 1 | 3 | | 1 |
| Natural Death | | | | 2 |
| Terminal Sacrifice | 24 | 21 | 27 | 22 |
| Animals Examined Microscopically | 27 | 27 | 27 | 27 |

ALIMENTARY SYSTEM

| | | | | |
|--------------------------------------------------------------|---------|---------|---------|---------|
| Esophagus | (27) | (26) | (27) | (27) |
| Gallbladder | (26) | (25) | (27) | (25) |
| Intestine Large, Cecum | (26) | (26) | (27) | (25) |
| Intestine Large, Colon | (26) | (26) | (27) | (25) |
| Intestine Large, Rectum | (26) | (26) | (27) | (26) |
| Intestine Small, Duodenum | (26) | (25) | (27) | (25) |
| Liver | (26) | (27) | (27) | (27) |
| Hepatocellular Adenoma | 3 (12%) | 2 (7%) | 6 (22%) | 9 (33%) |
| Hepatocellular Carcinoma | | 1 (4%) | | |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Mesentery | (0) | (2) | (1) | (0) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (50%) | | |
| Pancreas | (27) | (27) | (27) | (27) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Salivary Glands | (27) | (26) | (27) | (27) |
| Stomach, Forestomach | (26) | (26) | (27) | (27) |
| Squamous Cell Carcinoma | | 1 (4%) | | |
| Stomach, Glandular | (26) | (26) | (27) | (25) |
| Adenocarcinoma | | 1 (4%) | | |

CARDIOVASCULAR SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle 9 mo M | AZT 40 9 mo M | AZT 80 9 mo M | AZT 120 9 mo M |
|--------------------------------------------------------------|----------------|---------------|---------------|----------------|
| Blood Vessel | (27) | (27) | (27) | (27) |
| Heart | (27) | (27) | (27) | (27) |
| ENDOCRINE SYSTEM | | | | |
| Adrenal Cortex | (27) | (27) | (27) | (27) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Adrenal Medulla | (25) | (26) | (24) | (26) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Islets, Pancreatic | (27) | (27) | (27) | (27) |
| Parathyroid Gland | (16) | (20) | (21) | (22) |
| Pituitary Gland | (25) | (27) | (27) | (27) |
| Thyroid Gland | (26) | (27) | (27) | (26) |
| GENERAL BODY SYSTEM | | | | |
| Tissue NOS | (2) | (1) | (0) | (1) |
| Sarcoma | 1 (50%) | | | |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (100%) | | |
| GENITAL SYSTEM | | | | |
| Coagulating Gland | (0) | (1) | (0) | (0) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (100%) | | |
| Epididymis | (27) | (27) | (27) | (26) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Preputial Gland | (27) | (26) | (27) | (26) |
| Prostate | (27) | (27) | (27) | (25) |
| Seminal Vesicle | (26) | (27) | (27) | (26) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| Testes | (27) | (26) | (27) | (26) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle 9 mo M | AZT 40 9 mo M | AZT 80 9 mo M | AZT 120 9 mo M |
|-------------------------------------------------------------------------|----------------|---------------|---------------|----------------|
| HEMATOPOIETIC SYSTEM | | | | |
| Bone Marrow | (27) | (26) | (27) | (26) |
| Lymph Node | (0) | (1) | (0) | (1) |
| Lymph Node, Mandibular | (27) | (25) | (27) | (26) |
| Lymph Node, Mesenteric | (26) | (23) | (26) | (25) |
| Spleen | (26) | (25) | (27) | (25) |
| Thymus | (27) | (24) | (27) | (24) |
| Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| INTEGUMENTARY SYSTEM | | | | |
| Skin | (27) | (27) | (27) | (27) |
| Subcutaneous Tissue, Fibrosarcoma | | | | 1 (4%) |
| MUSCULOSKELETAL SYSTEM | | | | |
| Bone | (1) | (0) | (0) | (0) |
| Humerus, Osteosarcoma | 1 (100%) | | | |
| Bone, Femur | (27) | (27) | (27) | (27) |
| Osteosarcoma | 1 (4%) | | | |
| Skeletal Muscle | (27) | (27) | (27) | (27) |
| Diaphragm, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach | | 1 (4%) | | |
| NERVOUS SYSTEM | | | | |
| Brain, Cerebellum | (27) | (27) | (27) | (27) |
| Brain, Cerebrum | (27) | (27) | (27) | (27) |
| Olfactory Lobe, Neuroblastoma | | 1 (4%) | | 1 (4%) |
| RESPIRATORY SYSTEM | | | | |
| Lung | (27) | (27) | (27) | (27) |
| Alveolar/Bronchiolar Carcinoma | | 1 (4%) | | |
| Osteosarcoma, Metastatic, Bone, Femur | 1 (4%) | | | |
| Nose | (27) | (27) | (27) | (25) |

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle 9 mo M | AZT 40 9 mo M | AZT 80 9 mo M | AZT 120 9 mo M |
|-----------------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Neuroblastoma, Metastatic, Brain, Cerebrum | | 1 (4%) | | 1 (4%) |
| SPECIAL SENSES SYSTEM | | | | |
| Harderian Gland Adenoma | (27) 1 (4%) | (27) | (27) | (27) |
| URINARY SYSTEM | | | | |
| Kidney Urinary Bladder | (26) (27) | (27) (27) | (27) (27) | (26) (26) |
| SYSTEMIC LESIONS | | | | |
| Multiple Organs Lymphoma Malignant | *(27) 1 (4%) | *(27) 2 (7%) | *(27) 1 (4%) | *(27) 1 (4%) |

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS)

Time Report Requested: 11:51:06

Route: GAVAGE

CAS Number: 30516-87-1

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

| C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE | Vehicle 9 mo M | AZT 40 9 mo M | AZT 80 9 mo M | AZT 120 9 mo M |
|---------------------------------------|----------------|---------------|---------------|----------------|
|---------------------------------------|----------------|---------------|---------------|----------------|

Tumor Summary for Males

| | | | | |
|----------------------------------------------------------------------|---|----|---|----|
| Total Animals with Primary Neoplasms (b) | 8 | 7 | 7 | 12 |
| Total Primary Neoplasms | 8 | 9 | 7 | 12 |
| Total Animals with Benign Neoplasms | 4 | 2 | 6 | 9 |
| Total Benign Neoplasms | 4 | 2 | 6 | 9 |
| Total Animals with Malignant Neoplasms | 4 | 6 | 1 | 3 |
| Total Malignant Neoplasms | 4 | 7 | 1 | 3 |
| Total Animals with Metastatic Neoplasms | 1 | 2 | | 1 |
| Total Metastatic Neoplasms | 1 | 12 | | 1 |
| Total Animals with Malignant Neoplasms Uncertain Primary Site | | | | |
| Total Animals with Neoplasms Uncertain-Benign or Malignant | | | | |
| Total Uncertain Neoplasms | | | | |

*** END OF MALE ***

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors